NCT05956821 2025-12-08
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
University of Miami
Phase 1/2 Recruiting
Clinical Trials
9 trialsNCT01552434 2025-10-14
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT01884740 2022-08-09
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Weill Medical College of Cornell University
Phase 1/2 Terminated
NCT01012609 2022-03-14
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02855086 2020-03-31
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
Stanford University
Phase 1/2 Terminated
NCT01238237 2017-02-01
Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA
Northwell Health
Phase 1 Completed
NCT01044225 2012-03-22
Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma
Universitair Ziekenhuis Brussel
Phase 2 Terminated
NCT00463073 2008-12-11
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
Rigshospitalet, Denmark
Phase 2 Completed
NCT00311857 2006-09-08
Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)
Heidelberg University
Phase 1/2 Unknown